A Randomized, Open-Label Phase 3 Study of Amivantamab + FOLFIRI Versus Cetuximab/Bevacizumab + FOLFIRI in Participants with KRAS/NRAS and BRAF Wildtype Recurrent, Unresectable or Metastatic Colorectal Cancer Who Have Received Prior Chemotherapy

Protocol No
JNJ-61186372COR3002-ORIGAMI-3
Staff Member
James Thomas
Phase
III
Summary

This project is being done to compare the effects of amivantamab in combination with standard of care chemotherapy (FOLFIRI) against cetuximab or bevacizumab in combination with FOLFIRI.
Objective
A Study of Amivantamab and FOLFIRI Versus Cetuximab/Bevacizumab and FOLFIRI in Participants With KRAS/NRAS and BRAF Wild-type Colorectal Cancer Who Have Previously Received Chemotherapy (OrigAMI-3)
Study Sites
Froedtert Hospital
Status
OPEN TO ACCRUAL
Categories
Cancer, Gastrointestinal Cancers
ClinicalTrials.gov
https://www.clinicaltrials.gov/study/NCT06750094